New treatments for chronic viral hepatitis B and C

Bailliere's Clinical Gastroenterology

Volumn 10, Issue 2, 1996, Pages 299-333

  Dusheiko, Geoffrey M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; COLCHICINE; CORTICOSTEROID; FAMCICLOVIR; FIALURIDINE; FOSCARNET; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDOMETACIN; INTERLEUKIN 12; INTERLEUKIN 2; LAMIVUDINE; LEVAMISOLE; NUCLEOSIDE ANALOG; PHYLLANTHUS AMARUS EXTRACT; POLYADENYLIC POLYURIDYLIC ACID; RIBAVIRIN; THYMOSIN; URSODEOXYCHOLIC ACID; VIDARABINE;

BONE MARROW TRANSPLANTATION; CHEMICAL STRUCTURE; CHRONIC HEPATITIS; DRUG EFFICACY; DRUG WITHDRAWAL; DUCK; HEPATITIS B; HEPATITIS C; HORMONAL THERAPY; HUMAN; IMMUNOTHERAPY; LIVER CELL CULTURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW;

EID: 0029759886     PISSN: 09503528     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-3528(96)90009-3     Document Type: Article

References (155)

1. Alt M, Renz R, Hofschneider PH, Paumgartner G & Caselmann WH (1995) Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology 22: 707-717.
2. Angelico M, Gandin C, Pescarmona E et al (1995) Recombinant interferon-α and ursodeoxycholic acid versus interferon-α alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. American Journal of Gastroenterology 90: 263-269.
3. Aoki-Sei S, O'Brien MC, Ford H et al (1991) In vitro inhibition of hepatitis B virus replication by 2′,3′-dideoxyguanosine, 2′,3′-dideoxyinosine, and 3′-azido-2′,3′-dideoxythymidine in 2.2.15 (PR) cells. Journal of Infectious Diseases 164: 843-851.
4. Bach N, Schaffner F & Lin SC (1989) High-dose recombinant interleukin-2 for chronic viral hepatitis [letter]. Lancet ii: 281.
5. Bain VG, Daniels HM, Chanas A et al (1989) Foscarnet therapy in chronic hepatitis B virus e antigen carriers. Journal of Medical Virology 29: 152-155.
6. Beach JW, Jeong LS, Alves AJ et al (1992) Synthesis of enantiomerically pure (2′A,5′S)-(-)-1-[2-(hydroxymethyl)oxathiolan-5-yl]cytosine as a potent antiviral agent against hepatitis B virus (HBV) and human immunodeficiency virus (HIV). Journal of Organic Chemistry 57: 2217-2219.
7. Beloqui O, Prieto J, Suárez M et al (1993) N-acetyl cysteine enhances the response to interferon-α in chronic hepatitis C: a pilot study. Journal of Interferon Research 13: 279-282.
8. Berk L, Schalm SW, De Man RA et al (1992a) Failure of acyclovir to enhance the antiviral effect of α lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trial. Journal of Hepatology 14: 305-309.
9. Berk L, Schalm SW & Heijtink RA (1992b) Zidovudine inhibits hepatitis B virus replication. Antiviral Research 19: 111-118.
10. Bertoletti A, Chisari FV, Penna A et al (1993) Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. Journal of Virology 67: 2376-2380.
11. Bishop N, Civitico G, Wang YY et al (1990) Antiviral strategies in chronic hepatitis B virus infection: I. Establishment of an in vitro system using the duck hepatitis B virus model. Journal of Medical Virology 31: 82-89.
12. Blumberg BS, Millman I, Venkateswaran PS & Thyagarajan SP (1990) Hepatitis B virus and primary hepatocellular carcinoma: treatment of HBV carriers with Phyllanthus amarus. (1990) Vaccine 8 (supplement): S86-S92.
13. Boman S, Ballen JL & Seggev JS (1995) Dramatic responses to intravenous immunoglobulin in vasculitis. Journal of Internal Medicine 238: 375-377.
14. Boucher E, Jouanolle H, Andre P et al (1995) Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients. Hepatology 21: 322-327.
15. Braconier JH, Paulsen O, Engman K & Widell A (1995) Combined interferon-alpha and ribavirin treatment in chronic hepatitis C: a pilot study. Scandinavian Journal of Infectious Diseases 27: 325-329.
16. Brillanti S, Carson J, Foli M et al (1994) A pilot study of combination therapy with ribavirin plus interferon alfa for interferon-alfa-resistant chronic hepatitis C. Gastroenterology 107: 812-817.
17. Brunetto MR, Oliven F, Rocca G et al (1989) Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 10: 198-202.
18. Brunetto MR, Stemler M, Bonino F et al (1990) A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. Journal of Hepatology 10: 258-261.
19. Brunetto MR, Oliven F, Colombatto P et al (1995) Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha. Journal of Hepatology 22 (supplement 1): 42-44.
20. Brook MG, Karayiannis P & Thomas HC (1989a) Which patients with chronic hepatitis B virus infection will respond to interferon-alpha therapy? A statistical analysis of predictive factors. Hepatology 10: 761-763.
21. Brook MG, Petrovic L, McDonald JA et al (1989b) Histological improvement after anti-viral treatment for chronic hepatitis B virus infection. Journal of Hepatology 8: 218-225.
22. Carman WF, Jacyna MR, Hadziyannis S et al (1989) Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet ii: 588-591.
23. Caselmann WH, Eisenburg J, Hofschneider PH & Koshy R (1989) Beta- and gamma-interferon in chronic active hepatitis B. A pilot trial of short-term combination therapy. Gastroenterology 96: 449-455.
24. Catterall AP, Moyle GJ, Hopes EA et al (1992) Dideoxyinosine for chronic hepatitis B infection. Journal of Medical Virology 37: 307-309.
25. Chan S-W, Simmonds P, McOmish F et al (1991) Serological responses to infection with three different types of hepatitis C virus. Lancet 338: 1391.
26. Chang C-N, Doong S-L, Zhou JH et al (1992a) Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. Journal of Biological Chemistry 267: 13938-13942.
27. Chang C-N, Skalski V, Hua Zhou J & Cheng (1992b) Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. Journal of Biological Chemistry 267: 22414-22420.
28. Civitico G, Wang YY, Luscombe C et al (1990a) Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. Journal of Medical Virology 31: 90-97.
29. Civitico G, Wang YY, Luscombe C et al (1990b) Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. Journal of Medical Virology 31: 90-97.
30. Clemente MG, Congia M, Lai ME et al (1994) Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. Journal of Pediatrics 125: 123-128.
31. Cohard M, Poynard T, Mathurin P & Zarski JP (1994) Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis. Hepatology 20: 1390-1398.
32. Davis GL (1989) Interferon treatment of viral hepatitis in immunocompromised patients. Seminars in Liver Disease 9: 267-272.
33. Davis GL, Balart LA, Schiff ER et al (1989) Treatment of chronic hepatitis C with recombinant interferon-alfa. A multicenter randomized, controlled trial. New England Journal of Medicine 321: 1501-1506.
34. Davis HL, Schirmbeck R, Reimann J & Whalen RG (1995) DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. Human Gene Therapy 6: 1447-1456.
35. Dean J, Bowden S & Locarnini S (1995) Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir. Antiviral Research 27: 171-178.
36. Di Bisceglie AM, Shindo M, Fong T-L et al (1992) A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16: 649-654.
37. Di Bisceglie AM, Martin P, Kassianides C et al (1989) Recombinant interferon-alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. New England Journal of Medicine 321: 1506-1510.
38. Di Bisceglie AM, Rustgi VK, Kassianides C et al (1990) Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology 11: 266-270.
39. Di Stefano G, Busi C, Mattioli A & Fiume L (1995) Selective delivery to the liver of antiviral nucleoside analogs coupled to a high molecular mass lactosaminated poly-L-lysine and administered to mice by intramuscular route. Biochemical Pharmacology 49: 1769-1775.
40. Dusheiko GM & Zuckerman AJ (1991) Therapy for hepatitis B. Current Opinion in Infectious Diseases 4: 785-794.
41. Dusheiko GM, Main J, Thomas H et al (1996) Ribavirin treatment for patients with chronic hepatitis C. Results of a placebo controlled study. Journal of Hepatology (in press).
42. Farhat BA, Marinos G, Daniels HM et al (1995) Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. Journal of Hepatology 23: 21-27.
43. Fattovich G, Brollo L, Pontisso Pet al (1986) Levamisole therapy in chronic type B hepatitis. Results of a double blind randomized trial. Gastroenterology 91: 692-696.
44. Fattovich G, Giustina G, Brollo L et al (1992) Therapy for chronic hepatitis B with lymphoblastoid interferon-α and levamisole. Hepatology 16: 1115-1119.
45. Fattovich G, Giustina G, Alberti A et al (1994) A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. Journal of Hepatology 21: 361-366.
46. Fattovich G, McIntyre G, Thursz M et al (1995) Hepatitis B virus precore core variation and interferon therapy. Hepatology 22: 1355-1362.
47. Feinstone SM, Kapikian AZ, Purcell RH et a (1975)l Transfusion associated hepatitis not due to viral hepatitis type A or B. New England Journal of Medicine 292: 767-770.
48. Feray C, Samuel D, Thiers V et al (1992) Reinfection of liver graft by hepatitis C virus after liver transplantation. Journal of Clinical Investigation 89: 1361-1365.
49. Fernandez H, Banks G & Smith R (1986) Ribavirin: a clinical overview. European Journal of Epidemiology 2: 1-14.
50. Ferrell LD, Wright TL, Roberts J et al (1992) Hepatitis C viral infection in liver transplant recipients. Hepatology 16: 865-876.
51. Fiume L, Busi C, Di Stefano G & Mattioli A (1994) Targeting of antiviral drugs to the liver using glycoprotein carriers. Advances in Drug Delivery Reviews 14: 51-65.
52. Fiume L, Di Stefano G, Busi C et al (1995) Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly-L-lysine and administered by intramuscular route. Hepatology 22: 1072-1077.
53. Fourel I, Li J, Hantz O et al (1992) Effects of 2′-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks. Journal of Medical Virology 37: 122-126.
54. Fourel I, Cullen JM, Saputelli J et al (1994a) Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. Journal of Virology 68: 8321-8330.
55. Fourel I, Saputelli J, Schaffer P & Mason WS (1994b) The carbocyclic analog of 2′-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver. Journal of Virology 68: 1059-1065.
56. Fried MW, Korenman JC, Di Bisceglie AM et al (1992) A pilot study of 2′,3′-dideoxyinosine for the treatment of chronic hepatitis B. Hepatology 16: 861-864.
57. Furman PA, Davis M, Liotta DC et al (1992) The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrobial Agents and Chemotherapy 36: 2686-2692.
58. Garcia de Ancos JL, Roberts DA & Dusheiko GM (1990) An economic evaluation of the costs of a interferon treatment of chronic active hepatitis due to hepatitis B or C virus. Journal of Hepatology 11: s11-s18.
59. Gish RJ, Lau JYN, Brooks Let al (1996) Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 23: 1-7 (abstract).
60. Goodarzi G, Gross SC, Tewari A & Watabe K (1990) Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen. Journal of General Virology 71: 3021-3025.
61. Guéchot J, Poupon RE, Giral P et al (1994) Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. Journal of Hepatology 20: 388-393.
62. Hahm KB, Han KH, Kim WH et al (1994) Efficacy of polyadenylic polyuridylic acid in the treatment of chronic active hepatitis B. International Journal of Immunopharmacology 16: 217-225.
63. Hayashi H, Takikawa T, Nishimura N et al (1994) Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. American Journal of Gastroenterology 89: 986-988.
64. Hayashi H, Takikawa T, Nishimura N & Yano M (1995) Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. Journal of Hepatology 22: 268-271.
65. Heinrich D & Maier K-P (1995) Treatment of chronic viral hepatitis with acetylsalicylic acid. Schweiz Med Wochenschr 125: 755-757.
66. Hendricks DA, Stowe BJ, Hoo BS et al (1995) Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. American Journal of Clinical Pathology 104: 537-546.
67. Hiramatsu N, Hayashi N, Kasahara A et al (1995) Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon-alpha. Journal of Hepatology 22: 135-142.
68. Honkoop P, De Man RA, Heijtink RA & Schalm SW (1995) Hepatitis B reactivation after lamivudine. Lancet 346: 1156-1157.
69. Hope RL, Weltman M, Dingley J et al (1995) Interferon-alfa for chronic active hepatitis B. Long term follow-up of 62 patients: outcomes and predictors of response Medical Journal of Australia 162: 8-11.
70. Iizuka A, Watanabe T, Kubo T et al (1994) M13 bacteriophage DNA inhibits duck hepatitis B virus during acute infection. Hepatology 19: 1079-1087.
71. Ilan Y, Nagler A, Adler R et al (1993) Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology 18: 246-252.
72. Ilan Y, Nagler A, Shouval D et al (1994) Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors. Clinical and Experimental Immunology 97: 299-302.
73. Kaneko S, Miller RH, Di Bisceglie AM et al (1990) Detection of hepatitis B virus DNA in serum by polymerase chain reaction. Gastroenterology 99: 799-804.
74. Kassianides C, Hoofnagle JH, Miller RH et al (1989) Inhibition of duck hepatitis B virus replication by 2′,3′-dideoxycytidine. A potent inhibitor of reverse transcriptase. Gastroenterology 97: 1275-1280.
75. Kato N, Hijikata M, Nakagawa M et al (1991) Molecular structure of the Japanese hepatitis C viral genome. FEBS Letters 280: 325-328.
76. Korba BE & Gerin JL (1992) Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Research 19: 55-70.
77. Kos T, Molijn A, Blauw B & Schellekens H (1991) Baculovirus-directed high level expression of the hepatitis delta antigen in Spodoptera frugiperda cells. Journal of General Virology 72: 833-842.
78. Krogsgaard K (1994) Does corticosteroid pretreatment enhance the effect of interferon-alfa treatment in chronic hepatitis B. Journal of Hepatology 20: 159-162.
79. Kruger M, Tillmann C, Trautwein K et al (1995) Famciclovir treatment of hepatitis B virus recurrence after orthotopic liver transplantation - a pilot study. Hepatology 22: 449 (abstract).
80. Lake JR & Wright TL (1991) Liver transplantation for patients with hepatitis B: what have we learned from our results. Hepatology 13: 796-799.
81. Lau JYN, Lai CL, Wu PC et al (1991) A randomised controlled trial of recombinant interferon-gamma in Chinese patients with chronic hepatitis B virus infection. Journal of Medical Virology 34: 184-187.
82. Lee B, Luo WX, Suzuki S et al (1989) In vitro and in vivo comparison of the abilities of purine and pyrimidine 2′,3′-dideoxynucleosides to inhibit duck hepadnavirus. Antimicrobial Agents and Chemotherapy 33: 336-339.
83. Levin S, Leibowitz E, Torten J & Hahn T (1989) Interferon treatment in acute progressive and fulminant hepatitis. Israel Journal of Medical Science 25: 364-372.
84. Liaw Y-F, Sheen I-S, Chen T-J et al (1991) Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 13: 627-631.
85. Liaw Y-F, Lin S-M, Chen T-J et al (1994) Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: A randomized controlled trial. Journal of Hepatology 20: 175-180.
86. Lin C-Y (1995) Treatment of hepatitis B virus-associated membranous nephropathy with recombinant interferon-alpha. Kidney International 47: 225-230.
87. Lisker-Melman M, Webb D, Di-Bisceglie AM et al (1989) Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human interferon-alpha. Annals of Internal Medicine 111: 479-483.
88. Lofgren B, Nordenfelt E & Oberg B (1989) Inhibition of RNA- and DNA-dependent duck hepatitis B virus DNA polymerase activity by nucleoside and pyrophosphate analogs. (1989) Antiviral Research 12: 301-310.
89. Lok AS, Lai CL, Wu PC et al (1989) Treatment of chronic hepatitis B with interferon: experience in Asian patients. Seminars in Liver Disease 9: 249-253.
90. Mabit H, Dubanchet S, Capel F et al (1994) In vitro infection of human hepatoma cells (HepG2) with hepatitis B virus (HBV): spontaneous selection of a stable HBV surface antigen-producing HepG2 cell line containing integrated HBV DNA sequences. Journal of General Virology 75: 2681-2689.
91. McKenzie R, Fried NW, Sallie R et al (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. New England Journal of Medicine 333: 1099-1105.
92. McMillan JS, Shaw T, Angus PW & Locarnini SA (1995) Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 22: 36-43.
93. McOmish F, Chan S-W, Dow BC et al (1993) Detection of three types of hepatitis C virus in blood donors: Investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities. Transfusion 33: 7-13.
94. Marcellin P, Ouzan D, Degos F et al (1989a) Randomized controlled trial of adenine arabinoside 5′-monophosphate in chronic active hepatitis B: comparison of the efficacy in heterosexual and homosexual patients [see comments]. Hepatology 10: 328-331.
95. Marcellin P, Pialoux G, Girard PM et al (1989b) Absence of effect of zidovudine on replication of hepatitis B virus in patients with chronic HIV and HBV infection [letter]. New England Journal of Medicine 321: 1758
96. Marcellin P, Loriot MA, Boyer N (1990a) Recombinant human interferon-gamma in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects. Hepatology 12: 155-158.
97. Marcellin P, Martinot-Peignoux M, Loriot MA et al (1990b) Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy. Annals of Internal Medicine 112: 227-228.
98. Marcellin P, Samuel D, Areias J (1994) Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 19: 6-12.
99. Marcellin P, Pouteau M, Loriot MA et al (1995) Adenine arabinoside 5′-monophosphate in patients with chronic hepatitis B: comparison of the efficacy in patients with high and low viral replication. Gut 36: 422-426.
100. Martin P, Muñoz SJ, Di Bisceglie AM et al (1991) Recurrence of hepatitis C virus infection after orthotopic liver transplantation. Hepatology 13: 719-721.
101. Martín J, Quiroga JA, Bosch O & Carreño (1994) Changes in cytokine production during therapy with granulocyte-macrophage colony-stimulating factor in patients with chronic hepatitis B. Hepatology 20: 1156-1161.
102. Mason WS, Cullen J, Saputelli J (1994) Characterization of the antiviral effects of 2′ carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology 19: 398-411.
103. Matthes E, von Janta-Lipinski M, Will H et al (1992) Inhibition of hepatitis B virus production by modified 2′,3′-dideoxy-thymidine and 2′,3′-dideoxy-5-methylcytidine derivatives. In vitro and in vivo studies. Biochemical Pharmacology 43: 1571-1577.
104. Milich DR, Jones JE, Hughes JL et al (1990) Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero. Proceedings of the National Academy of Science of the USA 87: 6599-6603.
105. Milich DR, Wolf SF, Hughes JL & Jones JE (1995) Interleukin 12 suppresses autoantibody production by reversing helper T-cell phenotype in hepatitis B e antigen transgenic mice. Proceedings of the National Academy of Science of the USA 92: 6847-6851.
106. Minuk GY & LaFreniere R (1988) Interleukin-1 and interleukin-2 in chronic type B hepatitis. Gastroenterology 94: 1094-1096.
107. Minuk GY, German GB, Bernstein C et al (1992) A pilot study of steroid withdrawal followed by oral acyclovir in the treatment of chronic type B hepatitis. Clinical Investigative Medicine 15: 506-512.
108. Mizutani T, Kato N, Hirota M et al (1995) Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells. Biochemical and Biophysical Research Communications 212: 906-911.
109. Mutchnick MG, Appelman HD, Chung HT et al (1991) Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 14: 409-415.
110. Mutchnick MG, Ehrinpreis MN, Kinzie JL & Peleman RR (1994) Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents. Antiviral Research 24: 245-257.
111. Naoumov NV, Thomas MG, Mason AL et al (1995) Genomic variations in the hepatitis B core gene: a possible factor influencing response to interferon-alfa treatment. Gastroenterology 108: 505-514.
112. Nishiguchi S, Kuroki T, Nakatani S et al (1995) Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346: 1051-1055.
113. Ojwang JO, Bhattacharya BK, Marshall HB et al (1995) Inhibition of episomal hepatitis B virus DNA in vitro by 2,4-diamino-7-(2-deoxy-2-fluoro-β-D-abinofuranosyl)pyrrolo[2,3-d] pyrimidine. Antimicrobial Agents and Chemotherapy 39: 2570-2573.
114. Olynyk JK, Reddy KR, Di Bisceglie AM et al (1995) Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 108: 1104-1109.
115. Onji M, Kondoh K & Horiike N et al (1987) Effect of recombinant interleukin 2 on hepatitis e antigen positive chronic hepatitis. Gut 28: 1648-1652.
116. Oon CJ (1995) Natural lymphoblastoid α-interferon in the prevention of hepatocellular carcinoma in high-risk hepatitis B surface antigen (HBsAg) positive carriers: a 5-year follow-up. Proceedings of the Second International Symposium on Lymphoblastoid Alpha-Interferon. Barcelona, Spain, October 1994.
117. Par A, Paal M & Hollis I et al (1989) Immunomodulatory effect of isoprinosine in chronic active hepatitis B virus positive hepatitis: a comparitive study with levamisole. International Journal of Immunotherapy 5: 43-50.
118. Pardo M, Castillo I, Navas S & Carreño V (1995) Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alpha. Journal of Medical Virology 45: 439-444.
119. Perrillo RP, Schiff ER, Davis GL et al (1990) A randomized, controlled trial of interferon-alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group [see comments]. Comment in: New England Journal of Medicine 1990 Aug 2; 323(5): 337-9. New England Journal of Medicine 323: 295-301.
120. Perrillo RP, Schiff ER, Davis GL et al (1990) A randomized, controlled trial of interferon-alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group [see comments]. Comment in: New England Journal of Medicine 1990 Aug 2; 323(5): 337-9. New England Journal of Medicine 323: 295-301.
121. Perrillo R, Tamburro C, Regenstein F et al (1995) Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 109: 908-916.
122. Pol S (1995) Immunotherapy of chronic hepatitis B by anti HBV vaccine. Biomedical Pharmacotherapy 49: 105-109.
123. Pol S, Driss F, Michel M-L et al (1994) Specific vaccine therapy in chronic hepatitis B infection. Lancet 344: 342
124. Poterucha JJ, Rakela J, Lumeng Let al (1992) Diagnosis of chronic hepatitis C after liver transplantation by the detection of viral sequences with polymerase chain reaction. Hepatology 15: 42-45.
125. Quiroga JA, Mora I, Porres JC & Carreño V (1988) Elevation of 2′,5′-oligoadenylate synthetase activity and HLA-1 associated beta 2-microglobulin in response to recombinant interferon-gamma administration in chronic HBeAg-positive hepatitis. Journal of Interferon Research 8: 755-763.
126. Rakela J, Wood JR, Czaja AJ et al Parent K (1990) Long-term versus short-term treatment with recombinant interferon-alfa-2a in patients with chronic hepatitis B: a prospective, randomized treatment trial. Mayo Clinic Proceedings 65: 1330-1335.
127. Read AE, Donegan E, Lake J et al (1991) Hepatitis C in liver transplant recipients. Transplant Proceedings 23: 1504-1505.
128. Reichard O, Andersson J, Schvarcz R & Weiland O (1991) Ribavirin treatment for chronic hepatitis C. Lancet 337: 1058-1061.
129. Reichard O, Glaumann H & Weiland O (1994) Long-term histological outcome in patients with chronic hepatitis C treated repeatedly with interferon-alpha-2b without sustained response. Scandinavian Journal of Infectious Diseases 26: 383-389.
130. Reichen J, Bianchi L, Frei PC et al (1994) Efficacy of steroid withdrawal and low-dose interferon treatment in chronic active hepatitis B. Results of a randomized multicenter trial. Journal of Hepatology 20: 168-174.
131. Rensen PCN, van Dijk MCM, Havenaar EC et al (1995) Selective liver targeting of antivirals by recombinant chylomicrons - a new therapeutic approach to hepatitis B. Nature Medicine 1: 221-225.
132. Ruiz-Moreno M, Jimenez J, Porres JC et al (1990) A controlled trial of recombinant interferon-alpha in Caucasian children with chronic hepatitis B. Digestion 45: 26-33.
133. Schvarcz R, Hansson BG, Lernestedt J-O & Weiland O (1994) Treatment of chronic replicative hepatitis B virus infection with short-term continuous infusion of foscarnet. Infection 22: 330-332.
134. Schvarcz R, Yun ZB, Sönnerborg A & Weiland O (1995) Combined treatment with interferon-alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. Journal of Medical Virology 46: 43-47.
135. Shaw T, Amor P, Civitico G et al (1994) In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrobial Agents and Chemotherapy 38: 719-723.
136. Stevenson W, Gaffey M, Ishitani M et al (1995) Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection. Transplant Proceedings 27: 1219-1221.
137. Suou T, Hosho K, Kishimoto Y et al (1995) Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa. Hepatology 22: 426-431.
138. Takano S, Ito Y, Yokosuka O et al (1994) A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 20: 558-564.
139. Teran JC, Mullen KD, Hoofnagle JH & McCullough AJ (1994) Decrease in serum levels of markers of hepatic connective tissue turnover during and after treatment of chronic hepatitis B with interferon-α. Hepatology 19: 849-856.
140. Tsiquaye KN, Slomka MJ & Maung M (1994) Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. Journal of Medical Virology 42: 306-310.
141. Tur-Kaspa R, Teicher L, Laub O et al (1990) Interferon-alpha suppresses hepatitis B virus enhancer activity and reduces viral gene transcription. Journal of Virology 64: 1821-1824.
142. Unander DW, Webster GL & Blumberg BS (1995) Usage and bioassays in Phyllanthus (Euphorbiaceae). IV. Clustering of antiviral uses and other effects. Journal of Ethnopharmacology 45: 1-18.
143. Utili R, Sagnelli E, Gaeta GB et al (1994) Treatment of chronic hepatitis B in children with prednisone followed by interferon-alfa: a controlled randomized study. Journal of Hepatology 20: 163-167.
144. Varagona G, Brown D, Kibbler H et al (1992) Response, relapse and retreatment rates and viraemia in chronic hepatitis C treated with interferon-α 2b. A phase III study. European Journal of Gastroenterology and Hepatology 4: 707-712.
145. von Weizsäcker F, Blum HE & Wands JR (1992) Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template. Biochemical and Biophysical Research Communications 189: 743-748.
146. Wang Y-J, Lee S-D, Hsieh M-C et al (1994) A double-blind randomized controlled trial of colchicine in patients with hepatitis B virus-related postnecrotic cirrhosis. Journal of Hepatology 21: 872-877.
147. Wang MX, Cheng HW, Li YJ et al (1995a) Herbs of the genus Phyllanthus in the treatment of chronic patitis B: observations with three preparations from different geographic sites. Journal of Laboratory and Clinical Medicine 126: 350-352.
148. Wang Y, Luscombe C, Bowden S et al (1995b) Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovir-nalidixic acid. Antimicrobial Agents and Chemotherapy 39: 556-558.
149. Wen Y-M, Xiong S-D & Zhang W (1994) Solid matrix-antibody-antigen complex can clear viraemia and antigenaemia in persistent duck hepatitis B virus infection. Journal of General Virology 75: 335-339.
150. Whalen RG & Davis HL (1995) DNA-mediated immunization and the energetic immune response to hepatitis B surface antigen. Clinical Immunology and Immunopathology 75: 1-12.
151. Wong JB, Koff RS, Tinè F & Pauker SG (1995) Cost-effectiveness of interferon-α-2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Annals of Internal Medicine 122: 664-675.
152. Wright TL, Donegan E, Hsu HH et al (1992) Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 103: 317-322.
153. Yamaguchi S, Onji M, Kondoh H et al (1988) Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.Clinical and Experimental Immunology 74: 1-6.
154. Yokota T, Konno K, Chonan E et al (1990) Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro. Antimicrobial Agents and Chemotherapy 34: 1326-1330.
155. Zignego AL, Samuel D, Gigou M et al (1993) Patterns of hepatitis delta reinfection after liver transplantation and their evolution during a long term follow-up. Progress in Clinical and Biological Research 382: 409-417.